Startup Observer.com
  • Home
  • Industries
  • Innovation
  • outsourcing
  • Business
  • Finance
  • Headlines
  • Opinion
  • News
Home News Optellum announces strategic collaboration with the Lung Cancer Initiative at Johnson & Johnson applying AI to transform early lung cancer treatment
News

Optellum announces strategic collaboration with the Lung Cancer Initiative at Johnson & Johnson applying AI to transform early lung cancer treatment

by maria August 19, 2021
August 19, 2021
gawdo

Rapidly growing lung health startup aims to redefine early interception of lung cancer using artificial intelligence (AI) decision support software

OXFORD, UK / HOUSTON, USA – 18 August, 2021. Optellum, a lung-health AI company has entered a strategic collaboration with the Lung Cancer Initiative at Johnson & Johnson[1]. Through the collaboration, Optellum will apply its AI-powered clinical decision support platform with the goal of increasing lung cancer survival rates through early intervention and prevention.

Lung cancer is the most common type of cancer and the leading cause of cancer deaths in the world. Approximately 1.8 million people worldwide die from lung cancer each year. The current five-year survival rate is only 20%, primarily due to most patients being diagnosed after the disease has progressed to an advanced stage (Stage III or IV). However, the survival rate for small tumours treated at Stage IA is as high as 90%.

At the core of the collaboration is Optellum’s commercial software, Virtual Nodule Clinic, including an AI-powered digital biomarker based on neural networks and imaging analytics. It identifies and tracks at-risk patients and assigns a Lung Cancer Prediction score to lung nodules: small lesions, frequently detected in chest Computed Tomography (CT) scans that may or may not be cancerous. The Optellum AI will be used to drive accurate early diagnosis and optimal treatment decisions with the aim of treating patients earlier, potentially at a pre-cancerous stage, increasing survival rates.

The Optellum software achieved US Food and Drug Administration (FDA) clearance in March 2021 and is being implemented in clinical care by leading hospitals initially across the United States, with rollouts in select Asia-Pacific and European markets to follow. The software was extensively validated in multi-centre studies led by co-authors of clinical guidelines. In the clinical study underpinning the FDA clearance, all pulmonologists and radiologists in the study showed a statistically significant improvement in their diagnostic accuracy and consistency, and made more optimal clinical management decisions.

Optellum’s vision is to redefine the early intervention of lung cancer by enabling every patient to be diagnosed and treated at the earliest possible stage, when the chances of cure are highest. In addition to its lung cancer product portfolio, the company is exploring solutions applying the same technology platform to other deadly diseases of the lungs such as interstitial lung disease and COPD.

“This collaboration is a significant milestone for Optellum.” commented Václav Potěšil, PhD, founder and CEO of Optellum. Potěšil continued: “It brings us one step closer to Optellum’s vision of redefining early lung cancer treatment by helping every clinician, in every hospital to make the right decisions and provide their patients the best chance to fight back.”

Professor Sam Janes, MD, Head of the Respiratory Research Department at UCL Hospitals, Vice-Chair of the UK National Clinical Reference Group for Lung Cancer and member of the Optellum Medical Advisory Board, commented:

“I believe the next step in lung cancer diagnosis and treatment is seeing the emerging new technologies coming together. AI is key to enabling integration of imaging, clinical and molecular data – such as liquid biopsies – in order to diagnose disease even earlier. This convergence of technologies has tremendous potential to help physicians prevent, intercept and ultimately cure patients with early stage lung cancer.”

www.gawdo.com
Share on FacebookShare on TwitterShare on Linkedin
0 FacebookTwitterPinterestEmail
previous post
Who’s leading the AI race? Research reveals a deep divide across UK businesses
next post
ekko Starts Equity Crowdfunding on Seedrs – Pre-Registration Now Open

You may also like

Restart Scheme is ‘restarting’ careers across South West...

July 29, 2022

Zoho celebrates bumper year, after hitting 80 million...

July 28, 2022

UK workers reveal their top 20 ‘ideal jobs’

July 28, 2022
Editorial & Advertiser disclosureEditorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.
gawdo.com
https://www.gawdo.com
  • About us
  • Advertising & Terms of Use
  • Contact Us
  • Privacy Policy

@2021 - All Right Reserved.


Back To Top
Startup Observer.com
  • Home
  • Industries
  • Innovation
  • outsourcing
  • Business
  • Finance
  • Headlines
  • Opinion
  • News
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT